Pfizer's COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label
Portfolio Pulse from Vandana Singh
The FDA has revised the emergency use authorization for Pfizer's COVID-19 treatment Paxlovid. The EUA-labeled Paxlovid will remain authorized until March 8, 2024, or its expiration date, whichever comes first. After this date, only FDA-approved NDA-labeled Paxlovid will be available. This transition began on November 1, 2023, and affects pharmacies and healthcare providers. The PAXCESS program will offer free Paxlovid to eligible patients until December 31, 2024. Pfizer's stock (PFE) saw a minor decrease of 0.04% to $27.46.
January 29, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer's Paxlovid will transition from EUA to NDA labeling by March 8, 2024. The PAXCESS program continues to offer free medication to eligible patients until the end of 2024.
The FDA's revision of Paxlovid's EUA to a full NDA is a planned transition and is unlikely to have a significant short-term impact on Pfizer's stock price. The minor stock price movement reflects this. The continuation of the PAXCESS program may support positive sentiment, but the overall impact is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100